Anthony Clay, DO
Cardiovascular Disease · Newark, DENPI 1649202573
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,704 of the $36,570 with a category attached, or 81.2%. AstraZeneca accounts for 70.9% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $12,156 and has fallen 98.5% since, to $180 in 2025. Among cardiovascular disease clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $199.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$26K
- Sanofi-aventis U.S. LLC$7K
- Janssen Research & Development, LLC$1K
- Pfizer$796
- Akcea Therapeutics, Inc.$288
- E.r. Squibb & Sons, L.L.C.$268
- plus $1K from 18 others
Across 109 payments — averaging $20,830 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.7M
- GE HealthCare$410K
- Kowa Research Institute, Inc.$108K
- Novartis$6K
- Boehringer Ingelheim$5K
What the payments were for
- Consulting fees$1,6004%
- Speaking & faculty fees$29,70481%
- Travel & lodging$1,0363%
- Food & beverage$4,08011%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $25,934 |
| Sanofi-aventis U.S. LLC | 14 | $6,803 |
| Janssen Research & Development, LLC | 9 | $1,223 |
| Pfizer | 31 | $796 |
| Akcea Therapeutics, Inc. | 8 | $288 |
| E.r. Squibb & Sons, L.L.C. | 15 | $268 |
| Novartis | 16 | $258 |
| Johnson & Johnson | 11 | $246 |
| Merck | 2 | $194 |
| Amarin Pharma, Inc. | 10 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $79 |
| Esperion Therapeutics, Inc. | 5 | $70 |
| Lundbeck LLC | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Amgen | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 2 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Medtronic | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Gilead | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,570 in reported general payments places this provider in the 90th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 425 | $540,559 |
| XareltoRivaroxaban | 378 | $489,296 |
| EntrestoSacubitril/Valsartan | 93 | $134,826 |
| Repatha SureclickEvolocumab | 83 | $78,798 |
| FarxigaDapagliflozin Propanediol | 34 | $43,361 |
| Praluent PenAlirocumab | 20 | $25,647 |
| Metoprolol Succinate | 820 | $13,869 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $11,060 |
| BrilintaTicagrelor | 14 | $9,225 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 30 | $8,830 |
| Atorvastatin Calcium | 433 | $7,070 |
| VascepaIcosapent Ethyl | 15 | $6,963 |
| Rosuvastatin Calcium | 272 | $5,868 |
| Valsartan | 126 | $5,401 |
| Amlodipine Besylate | 501 | $4,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $796 | $540,559425 claims |
| Johnson & JohnsonXarelto | $246 | $489,296378 claims |
| NovartisEntresto | $258 | $134,82693 claims |
| AstraZenecaFarxiga, Brilinta | $25,934 | $52,58648 claims |
| Esperion Therapeutics, Inc.Nexlizet | $70 | $11,06014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
- Francis PalermoNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.